Antibody
- +1 609-736-0910
- [email protected]
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1090 |
Product Name |
High-Quality Bevacizumab Biosimilar: Anti-Human VEGFA mab- Research Grade |
Chemical Formula |
C6638H10160N1720O2108S44 |
Tags |
Bevacizumab Biosimilar, Bevacizumab, VEGFA, avastin, abatacept biosimilar, biosimilar antibodies, biosimilar monoclonal antibodies, 216974-75-3, vegfa protein, anti vegfa antibody |
Host |
CHO Cells |
Species |
Human |
Clonity |
Monoclonal |
Target |
VEGFA[Homo sapiens] |
CAS Number |
216974-75-3 |
Molecular Weigh |
149.15 KDa |
Alias |
12-IgG1, F(ab)-12 IgG1 |
Isotype |
IgG1 Kappa |
Size |
1mg, 5mg |
Research area |
Cancer |
Application |
FC, IP, ELISA, Neut, FuncS, IF, ICC |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Purity |
>95% as determined by SDS-PAGE |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. Avoid repeated freezing and thawing. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
FAQ
-
+ -
How do I apply for a quotation for bulk products?
Determine the specific product or products you are interested in purchasing in bulk. This may include recombinant proteins, antibodies, or other biological reagents. Please Contact us at [email protected]
-
+ -
What are the shipping conditions for antibody?
Antibodies are typically shipped at 2-8°C (refrigerated temperature). Antibodies should be packaged in appropriate containers to protect them from physical damage and temperature fluctuations. Some antibodies, especially those that are highly sensitive or prone to degradation, may require shipping on dry ice (−78.5 °C) to maintain a frozen state.
-
+ -
Do biosimilars work as well?
Biosimilars are designed to work as well as their reference products. Regulatory agencies require extensive comparative studies to demonstrate similarity in terms of safety, efficacy, and clinical outcomes. Clinical trials and real-world evidence support the effectiveness of biosimilars in treating the same conditions as their reference products.
-
+ -
Are biosimilars safe?
Biosimilars undergo rigorous regulatory scrutiny to ensure their safety profile is comparable to that of the reference products. Extensive preclinical and clinical studies are conducted to assess safety, including pharmacokinetics, pharmacodynamics, immunogenicity, and adverse event monitoring. Biosimilars are held to the same safety standards as reference products.